UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 525

Sortiert nach

Current treatment status of older patients with gynecological cancers

Japanese journal of clinical oncology, 2022-08, Vol.52 (8), p.825-832

2022

Link zum Volltext

Verfügbarkeit prüfen

PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy

Japanese journal of clinical oncology, 2019-08, Vol.49 (8), p.703-707

2019

Link zum Volltext

Verfügbarkeit prüfen

Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study

Gynecologic oncology, 2018-01, Vol.148 (1), p.139-146

2018

Link zum Volltext

Verfügbarkeit prüfen

Risk factors of stress fractures due to the female athlete triad: Differences in teens and twenties

Scandinavian journal of medicine & science in sports, 2019-10, Vol.29 (10), p.1501-1510

2019

Link zum Volltext

Verfügbarkeit prüfen

Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)

Japanese journal of clinical oncology, 2017-10, Vol.47 (10), p.986-990

2017

Link zum Volltext

Verfügbarkeit prüfen

IL-33 Exacerbates Endometriotic Lesions via Polarizing Peritoneal Macrophages to M2 Subtype

Reproductive sciences (Thousand Oaks, Calif.), 2020-03, Vol.27 (3), p.869-876

2020

Link zum Volltext

Verfügbarkeit prüfen

Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602

Japanese journal of clinical oncology, 2021-02, Vol.51 (2), p.205-212

2021

Link zum Volltext

Verfügbarkeit prüfen

Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives

Japanese journal of clinical oncology, 2015-05, Vol.45 (5), p.408-410

2015

Link zum Volltext

Verfügbarkeit prüfen

Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions

Expert review of anticancer therapy, 2011-07, Vol.11 (7), p.1055-1069

2011

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma

Cancer science, 2012-05, Vol.103 (5), p.926-932

2012

Link zum Volltext

Verfügbarkeit prüfen

Quantitative analysis of ovarian cysts and tumors by using T2 star mapping

The journal of obstetrics and gynaecology research, 2020-01, Vol.46 (1), p.140-146

2020

Link zum Volltext

Verfügbarkeit prüfen

Sphingosine I Phosphate (S1P) Increased IL-6 Expression and Cell Growth in Endometriotic Cells

Reproductive sciences (Thousand Oaks, Calif.), 2019-11, Vol.26 (11), p.1460-1467

2019

Link zum Volltext

Verfügbarkeit prüfen

The Clinical Features of Recurrent Endometrial Cancer in Japan: Chemotherapy Instead of Radiotherapy as Postoperative Adjuvant Treatment

International journal of gynecological cancer, 2018-10, Vol.28 (8), p.1616-1623

2018

Link zum Volltext

Verfügbarkeit prüfen

Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation

Gynecologic oncology, 2009-07, Vol.114 (1), p.69-74

2009

Link zum Volltext

Verfügbarkeit prüfen

Minimization of curative surgery for treatment of early cervical cancer: a review

Japanese journal of clinical oncology, 2015-07, Vol.45 (7), p.611-616

2015

Link zum Volltext

Verfügbarkeit prüfen

Comparison between Upfront Primary Debulking Surgery and Interval Debulking Surgery Following Neoadjuvant Chemotherapy for Primary Treatment of Ovarian Cancer

Gan to kagaku ryoho, 2019-02, Vol.46 (2), p.236

Onda, Takashi

2019

Link zum Volltext

Verfügbarkeit prüfen

Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206

Gynecologic oncology, 2009-04, Vol.113 (1), p.57-62

2009

Link zum Volltext

Verfügbarkeit prüfen

Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101)

Japanese journal of clinical oncology, 2015-01, Vol.45 (1), p.123-126

2015

Link zum Volltext

Verfügbarkeit prüfen

A case of vaginal clear cell adenocarcinoma complicated with congenital anomalies of the genitourinary tract and metanephric remnant without prenatal diethylstilbestrol exposure

The journal of obstetrics and gynaecology research, 2010-06, Vol.36 (3), p.681-685

2010

Link zum Volltext

Verfügbarkeit prüfen

Phase III Trial of Upfront Debulking Surgery Versus Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers: Japan Clinical Oncology Group Study JCOG0602

Japanese journal of clinical oncology, 2008-01, Vol.38 (1), p.74-77

2008

Link zum Volltext

Verfügbarkeit prüfen

Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?

Journal of radiation research, 2015-03, Vol.56 (2), p.354-359

2015

Link zum Volltext

Verfügbarkeit prüfen

Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy

Cancer science, 2011-05, Vol.102 (5), p.1068-1075

2011

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Impact of the History of Breast Cancer and of Hormone Therapy in Uterine Carcinosarcoma

International journal of gynecological cancer, 2012-02, Vol.22 (2), p.280-285

2012

Link zum Volltext

Verfügbarkeit prüfen

The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal Based on Interval Look During Upfront Surgery Setting Treatment

Japanese journal of clinical oncology, 2010-01, Vol.40 (1), p.36-41

2010

Link zum Volltext

Verfügbarkeit prüfen

Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial

European journal of cancer (1990), 2020-05, Vol.130, p.114-125

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 525

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(371)
Mit Volltextzugriff
(439)

Publikationsform

Sprache

Englisch
(443)
Japanisch
(250)
Koreanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Current treatment status of older patients with gynecological cancers

PARP inhibitors for BRCA wild type ovarian cancer; gene alterations, homologous recombination deficiency and combination therapy

Prognostic factors and optimal therapy for stages I–II neuroendocrine carcinomas of the uterine cervix: A multi-center retrospective study

Risk factors of stress fractures due to the female athlete triad: Differences in teens and twenties

Phase III trial to confirm the superiority of pelvic and para-aortic lymphadenectomy to pelvic lymphadenectomy alone for endometrial cancer: Japan Clinical Oncology Group Study 1412 (SEPAL-P3)

IL-33 Exacerbates Endometriotic Lesions via Polarizing Peritoneal Macrophages to M2 Subtype

Stage III disease of ovarian, tubal and peritoneal cancers can be accurately diagnosed with pre-operative CT. Japan Clinical Oncology Group Study JCOG0602

Pharmacotherapy for recurrent ovarian cancer: current status and future perspectives

Neoadjuvant chemotherapy for advanced ovarian cancer: overview of outcomes and unanswered questions

Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma

Quantitative analysis of ovarian cysts and tumors by using T2 star mapping

Sphingosine I Phosphate (S1P) Increased IL-6 Expression and Cell Growth in Endometriotic Cells

The Clinical Features of Recurrent Endometrial Cancer in Japan: Chemotherapy Instead of Radiotherapy as Postoperative Adjuvant Treatment

Radical hysterectomy for FIGO stage IIB cervical cancer: Clinicopathological characteristics and prognostic evaluation

Minimization of curative surgery for treatment of early cervical cancer: a review

Comparison between Upfront Primary Debulking Surgery and Interval Debulking Surgery Following Neoadjuvant Chemotherapy for Primary Treatment of Ovarian Cancer

Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206

Non-randomized confirmatory trial of modified radical hysterectomy for patients with tumor diameter 2 cm or less FIGO Stage IB1 uterine cervical cancer: Japan Clinical Oncology Group Study (JCOG1101)

A case of vaginal clear cell adenocarcinoma complicated with congenital anomalies of the genitourinary tract and metanephric remnant without prenatal diethylstilbestrol exposure

Phase III Trial of Upfront Debulking Surgery Versus Neoadjuvant Chemotherapy for Stage III/IV Ovarian, Tubal and Peritoneal Cancers: Japan Clinical Oncology Group Study JCOG0602

Assessment of transposed ovarian movement: how much of a safety margin should be added during pelvic radiotherapy?

Novel virtual cytological analysis for the detection of endometrial cancer cells using autoscan fluoromicroscopy

Prognostic Impact of the History of Breast Cancer and of Hormone Therapy in Uterine Carcinosarcoma

The Optimal Debulking after Neoadjuvant Chemotherapy in Ovarian Cancer: Proposal Based on Interval Look During Upfront Surgery Setting Treatment

Comparison of survival between primary debulking surgery and neoadjuvant chemotherapy for stage III/IV ovarian, tubal and peritoneal cancers in phase III randomised trial

Suchergebnisse filtern